Traditional drug-based treatments for inflammatory bowel disease (IBD) have significant
limitations due to their potential off-target systemic side-effects. Currently, there is a lack of …

Abnormal activation of the gut mucosal immune system and a highly dysregulated gut
microbiota play essential roles in the progression of inflammatory bowel disease (IBD). The …

Inflammatory bowel disease (IBD) is characterized by an inappropriate and persistent
inflammatory immune response and is often accompanied by excessive reactive oxygen …

Inflammatory bowel disease (IBD) is a refractory disorder characterized by chronic and
recurrent inflammation. The progression and pathogenesis of IBD is closely related to …

Ulcerative colitis (UC) is a chronic or relapsing inflammatory disease with limited therapeutic
outcomes. Pterostilbene (PSB) is a polyphenol-based anti-oxidant that has received …

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying
efficacy and underlying safety problems have limited their clinical application. Herein …

Colonic epithelial damage and dysregulated immune response are crucial factors in the
progression and exacerbation of inflammatory bowel disease (IBD). Nanoenabled targeted …

Oxidative stress, resulting from excessive generation of reactive oxygen species (ROS),
plays a pivotal role in the initiation and progression of inflammatory bowel disease (IBD). To …

Inflammatory bowel disease (IBD) involves chronic inflammation, loss of epithelial integrity,
and gastrointestinal microbiota dysbiosis. Effective therapies for IBD have not been …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …